Schrodinger, Inc. Stock Price, News & Analysis

Schrödinger, Inc. (Nasdaq: SDGR) announced on June 13, 2021, the grant of non-statutory stock options for 32,850 shares to 14 new employees. This action, part of the 2021 Inducement Equity Incentive Plan, was aimed at encouraging the employees to join the company. Each option has an exercise price of $77.51, equal to the stock's closing price on June 11, 2021. The options vest over four years, with a portion vesting after the first year and the remainder in monthly installments thereafter. Schrödinger continues to leverage its software platform for innovative drug and materials discovery.

Schrödinger (Nasdaq: SDGR) announced its participation in two upcoming virtual conferences. Management will present at the Jefferies Virtual Healthcare Conference on June 1, 2021, at 3:00 p.m. ET, followed by a presentation at the Goldman Sachs 42nd Annual Global Healthcare Conference on June 8, 2021, at 4:40 p.m. ET. Both presentations will be accessible on Schrödinger’s website under 'News & Events' for approximately 14 days. Schrödinger's innovative software platform accelerates the discovery of therapeutic and material solutions.

Schrödinger, Inc. (Nasdaq: SDGR) announced on May 15, 2021, the granting of stock options to 11 newly hired employees, totaling 22,775 shares. The options, part of the 2021 Inducement Equity Incentive Plan, have an exercise price of $61.24 per share and vest over four years. This initiative aims to attract talent by enhancing employment compensation. Schrödinger is known for its physics-based software platform that accelerates therapeutic and material discovery, aiding various sectors globally.

Schrödinger, Inc. (Nasdaq: SDGR) reported first-quarter 2021 financial results, noting a 23% increase in revenue to $32.1 million compared to Q1 2020. Software revenue grew 11%, while drug discovery revenue surged from $2.4 million to $5.8 million. Gross profit rose to $16.2 million despite a decline in software gross margin to 78%. Operating expenses increased significantly to $40.1 million. The company continues to advance its internal drug discovery pipeline and has expanded its collaboration with AstraZeneca. For 2021, Schrödinger expects total revenue between $124 million and $142 million.

Schrödinger (Nasdaq: SDGR) is set to present a corporate overview at the Bank of America Securities 2021 Virtual Healthcare Conference on May 11, 2021, at 3:30 pm ET. This innovative company is revolutionizing therapeutic and material discovery through its advanced physics-based software platform, allowing for faster and cost-effective development of high-quality molecules. The live webcast will be available in the investors section of Schrödinger’s website and will be archived for 14 days. Founded in 1990, Schrödinger has over 450 employees and operates globally across more than 70 countries.

Schrödinger (Nasdaq: SDGR) will host a conference call and webcast on May 11, 2021, at 8:30 a.m. ET to discuss its first quarter 2021 financial results and provide a business update. The live event can be accessed via the company's investor relations page. Schrödinger utilizes a physics-based software platform for rapid and cost-effective discovery of therapeutics and materials, serving biopharmaceutical companies, academic institutions, and government laboratories globally. Founded in 1990, the company operates with over 450 employees across more than 70 countries.

On April 13, 2021, Schrödinger, Inc. (Nasdaq: SDGR) granted non-statutory stock options for 7,450 shares to three new employees as part of their compensation under the 2021 Inducement Equity Incentive Plan. The options have an exercise price of $75.53 per share and a ten-year term, with a four-year vesting schedule. Schrödinger's physics-based software platform enhances the discovery of therapeutics and materials more efficiently than traditional methods. The company, founded in 1990, has over 450 employees and operates globally across various sectors.

Schrödinger (Nasdaq: SDGR) showcased promising preclinical data for its CDC7 inhibitor program at the AACR Annual Meeting on April 10, 2021. The data revealed that the company's picomolar CDC7 inhibitors effectively inhibited tumor cell growth, both individually and in conjunction with existing cancer treatments. The inhibitors demonstrated strong selectivity by inducing cancer cell apoptosis while sparing healthy cells, particularly in mouse models of acute myeloid leukemia and colorectal cancer. Schrödinger plans to advance these findings into IND-enabling studies in 2022.

Schrödinger (Nasdaq: SDGR) announced that its CEO, Ramy Farid, Ph.D., will participate in the BMO BioPharma Spotlight Series on Technology-Enabled Drug Discovery. The virtual panel is scheduled for Friday, April 16, at 10:00 a.m. ET. An on-demand webcast will be available on Schrödinger's website under the 'News & Events' section and will remain accessible for about seven days. Schrödinger is revolutionizing drug and material discovery through its physics-based software platform, which enhances the speed and cost-effectiveness of developing novel therapeutics.